
Antibody-Drug Conjugates and Cancer Treatment: Making "Smart Bombs" Smarter
Significant advances have been made in recent years to develop therapeutic agents beyond the “blunderbuss” approach of broadly targeting all rapidly dividing cells, to ones that better target tumor cells; specifically to improve the killing of tumor cells while reducing collateral damage to healthy tissues.The first generation of such targeted therapies include the development of monoclonal antibodies such as Herceptin for HER2-positive breast cancer and Rituxan for CD20-positive lymphomas...